Scientists develop new vaccine for urinary tract infections

Credit: CC0 Public Domain

Anyone who has ever developed a urinary tract infection (UTI) knows that it can be painful, pesky and persistent.

UTIs have a high recurrence rate and primarily afflict women—as many as 50% of women will experience at least one UTI during their lifetime.

In a new study, researchers describe a new vaccination strategy that they think could re-program the body to fight off the bacteria that cause urinary tract infections.

The research was conducted by a team from Duke University.

There are currently no effective UTI vaccines available for use in the U.S. in spite of the high prevalence of bladder infections.

In the study, the team describes the potential for a highly effective bladder vaccine that can not only eradicate residual bladder bacteria but also prevent future infections.

The strategy, which the team showed to be effective in mouse models, involves re-programming an inadequate immune response that the team identified last year.

They observed that when mouse bladders get infected with E. coli bacteria, the immune system dispatches repair cells to heal the damaged tissue while launching very few warrior cells to fight off the attacker.

This causes bacteria to never fully clear, living on in the bladder to attack again.

According to the team, the new vaccine strategy attempts to ‘teach’ the bladder to more effectively fight off the attacking bacteria.

By administering the vaccine directly into the bladder where the residual bacteria harbor, the highly effective vaccine antigen, in combination with an adjuvant known to boost the recruitment of bacterial clearing cells, performed better than traditional intramuscular vaccination.

The researchers reported that bladder-immunized mice effectively fought off infecting E. coli and eliminated all residual bladder bacteria, suggesting the site of administration could be an important consideration in determining the effectiveness of a vaccine.

They say they are encouraged by these findings, and since the individual components of the vaccine have previously been shown to be safe for human use, undertaking clinical studies to validate these findings could be done relatively quickly.

One author of the study is Soman Abraham, Ph.D.

The study is published in the Proceedings of the National Academy of Sciences.

Copyright © 2021 Knowridge Science Report. All rights reserved.